Reduction the Duration of Antibiotic Therapy in the Elderly (PROPAGE)

Grenoble Alpes University Hospital Center (CHU)

Status: Terminated

Conditions: Lung Infection

Treatments: Other: procalcitonine

Study type: Interventional

Funder types: Other

Identifiers

NCT02173613

1120

Details and patient eligibility

About

The main objective is to evaluate the interest of the repeated measurement of procalcitonin in patients with pulmonary infection to reduce the duration of antibiotic therapy in comparison with a conventional clinical strategy.

Enrollment: 117 patients

Sex: All

Ages: 80+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 80 years
• Started antibiotics for a chest infection
• Procalcitonin performed J0 antibiotic treatment
• Person affiliated to the social security

Exclusion criteria

• Patients with a documented infection with germs after Listeria spp, Legionella pneumophilia, Mycobacterium tuberculosis
• Patients with a documented infection with a virus or parasite (eg hemorrhagic fever, malaria)
• Patients with endovascular infection associated (endocarditis, pacemaker. Intravascular catheter)
• Patients with lung abscess associated upon entry Patients with a chronic infection associated
• Patients with severe immunosuppression (HIV or transplant)
• Palliative patient
• Death within 24 hours of admission to nursing units.
• Presence of antibiotic treatment for chronic infection.
• Patient under guardianship, curatorship or any other administrative or judicial action or deprivation of the right or freedom
• Patients hospitalized without their consent

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

117 participants in 2 patient groups

Procalcitonine

Experimental group

Description:

every 2 days, they will receive the dose of PCT and decide to stop antibiotic treatment according to the algorithm 2. They will notify the results of clinical evaluations in the electronics and all adverse event report forms.

Treatment:

Other: procalcitonine

contrôle

No Intervention group

Description:

Only clinical reassessments will be conducted and documented. Data on antibiotic will be listed and all adverse events. Data on the PCT from D2 to D4, D6, D8 and D15 output or will not be available to the prescriber.